Matej Mikulic
Research expert covering health, pharma & medtech
Roche - Statistics & Facts
With 2025 total sales of 61.5 billion francs, Swiss company Roche operates at a scale that typically supports sustained investment capacity. Continued year-on-year sales expansion would usually translate into greater flexibility to fund late-stage development and lifecycle management while buffering competitive pressure and currency-driven volatility. The divisional split reinforces this resilience: in 2025, Pharmaceuticals generated about 48 billion Swiss francs in sales while Diagnostics contributed about 14 billion. A Pharma-led earnings engine with a meaningful second pillar tends to reduce dependence on any single demand pattern—even though Pharmaceuticals will remain the primary driver of valuation and sentiment.
Strength in clusters
Concentration is notable but still within a “franchise portfolio” profile. In 2025, Ocrevus, Hemlibra, and Vabysmo together represented exactly one third of total pharmaceutical sales, meaning strong execution from a few brands can carry near-term delivery, while any stumble would need to be offset by broader launches and indications. On mix, oncology remained the largest therapeutic area at 32% of pharma revenues in 2025. The continued decline in oncology share over recent years implies that incremental growth increasingly needs to come from other areas (e.g., hematology) to keep the portfolio balanced.
R&D-powered renewal
Roche’s innovation stance remains clearly the company's focus. R&D expenditure reached 13.4 billion Swiss francs in 2025, increasing versus the previous year, which supports the interpretation that Roche is prioritizing portfolio renewal over pure near-term margin optimization. Pipeline breadth underpins this: as of January 2026, Roche reported 40 NMEs and six additional indications in Phase I, and projects progressing toward registration—helpful cushioning when mature products face erosion, but also a reminder that clinical and regulatory cadence remains a key swing factor for outlook and investor confidence.
Outlook
Roche’s outlook looks steady but execution-dependent: with growth returning at group level, investor focus is likely to stay on whether upcoming launches and label expansions can broaden the portfolio while competition rises in the largest therapy areas. Concentration remains manageable but worth monitoring. In 2025, Roche’s top three products (Ocrevus, Hemlibra, Vabysmo) accounted for exactly one third of total pharmaceutical sales—large enough that continued franchise momentum matters for delivery, but not so high that the equity story rests on a single asset.
Two Roche-specific overlays stand out. First, the company’s Pharmaceuticals business is U.S.-skewed, which increases sensitivity to U.S. access and pricing policy, including the Inflation Reduction Act’s Medicare drug price negotiation rollout. Second, on trade/tariffs, Roche’s risk is less about end-demand and more about operational friction (inputs, cross-border steps, compliance). Roche’s stated U.S. manufacturing investment plans can provide optionality to localise parts of the supply chain, although tariffs can still raise complexity and costs across multi-step pharma production networks.
